Compare the testing and safety evidence expected for cosmetics in the United States and Canada, including the implications of MoCRA and the different treatment of products falling under over-the-counter drug rules. The session will highlight where North American expectations diverge from EU practice and what cross-border manufacturers and regulatory teams need to assess before relying on existing data.